Aligos Therapeutics Inc expected to post a loss of $2.16 a share - Earnings Preview

Aligos Therapeutics

29/10/2024 13:58

* Aligos Therapeutics Inc  ALGS.OQ   ALGS.O  is expected
to show a
fall in quarterly revenue when it reports  results on October 31
(estimated) for the period ending September 30 2024
    * The South San Francisco California-based  company is
expected to
report a 89.7% decrease in revenue to $333.33 thousand from
$3.24 million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Aligos Therapeutics Inc
is for
a loss of $2.16 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $75.00​, above​ its last closing price
of $8.87. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -4.00       -4.00      0.80      Beat    120
 Jan. 1 2024   -4.75       -4.75      -5.50     Missed  -15.8
 Dec. 31 2023  -2.75       -6.75      -5.50     Beat    18.5​
 Sep. 30 2023  -11.73      -11.87     -10.25    Beat    13.7
 ​​Jun.        -12.19      -12.37     -10.75    Beat    13.1
 30 2023                                                
 Mar. 31 2023  -11.93      -12.12     -13.25    Missed  -9.3​
 Dec. 31 2022  -11.45      -11.80     -12.75    Missed  -8.1
 Sep. 30 2022  -14.02      -14.50     -11.00    Beat    24.1
 This summary was machine generated October 29 at 13:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)